Innate Pharma, Novo Nordisk develop cancer immunotherapy
Innate Pharma SAS (anticancer immunotherapy based on nonconventional lymphocytes) licensed Novo Nordisk AS exclusive research, development, and commercialization rights to a new class of immunomodulatory antibodies based on a family of receptor targets expressed by natural killer (NK) cells.
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com